Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

Abstract Introduction Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patien...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Dermatology and Therapy
المؤلفون الرئيسيون: April W. Armstrong, Steven R. Feldman, Timothy Fitzgerald, Theodore Alkousakis, Adam Sima, Alvin Li, Hyung-Joo Kang, Sandra I. Main, Saakshi Khattri, Linda Stein Gold
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Adis, Springer Healthcare 2025-06-01
الموضوعات:
Biologics
Body surface area
Patient-reported outcomes
Psoriasis
الوصول للمادة أونلاين:https://doi.org/10.1007/s13555-025-01456-5

الانترنت

https://doi.org/10.1007/s13555-025-01456-5

مواد مشابهة